Work

A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.14031

Authors: R. Salgia, D. S. Hong, L. H. Camacho, C. S. Ng, L. Janisch, M. J. Ratain, R. Kurzrock

Institution: University of Chicago

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2211326371

Cites:

Cited by: 34

Related to: 10